Streetbeat News

BGLC

BioNexus Gene Lab Corp.

https://www.bionexusgenelab.com

Industry

Medical - Diagnostics & Research

BioNexus Gene Lab Corp., through its subsidiary, Chemrex Corporation Sdn. Bhd., engages in the wholesale of chemical raw material products in Malaysia, Indonesia, Vietnam, and other countries in Southeast Asia. Its chemical raw material products used to produce handrails, bench tops, automotive and aero parts, cleanroom panels, and instruments. The company, through its subsidiary, BioNexus Gene Lab Sdn. Bhd, is also involved in developing and providing non-invasive liquid biopsy tests for the early detection of biomarkers. The company was incorporated in 2017 and is based in Kuala Lumpur, Malaysia.

Open

0.36

Mkt cap

6.3M

Volume

62K

High

0.37

P/E Ratio

-2.34

52-wk high

3.39

Low

0.34

Div yield

N/A

52-wk low

0.31

U.S. stocks traded higher with the Dow Jones gaining around 50 points. American Express Company (AXP) reported better-than-expected earnings for its second quarter and reaffirmed its FY23 outlook. Digital World Acquisition Corp. (DWAC), Evelo Biosciences, Inc. (EVLO), and BioNexus Gene Lab Corp (BGLC) saw their shares rise significantly. Sigma Additive Solutions, Inc. (SASI), RedHill Biopharma Ltd. (RDHL), and Priveterra Acquisition Corp. (PMGM) experienced a drop in their shares.

Portfolio Pulse from Lisa Levin

July 21, 2023 | 1:53 pm

US stocks traded mixed with the Nasdaq Composite falling nearly 250 points. Digital World Acquisition Corporation (DWAC) settled fraud charges with the SEC related to material misrepresentations made to investors. Guardforce AI (GFAI) announced a partnership with Concorde to provide automated security solutions in Singapore. Tesla (TSLA) reported quarterly record revenue of $24.93 billion. BioNexus Gene Lab (BGLC) announced the pricing of its Public Offering of 1,250,000 shares. Sirius XM (SIRI) shares surged on abnormally high volumes and were halted several times for volatility.

Portfolio Pulse from Benzinga Neuro

July 21, 2023 | 1:29 am

BioNexus Gene Lab Corp. has announced the pricing of its public offering of 1,250,000 shares at $4.00 per share, totaling $5 million. The company has also granted the underwriter an option to purchase up to an additional 187,500 shares. The shares have been approved for listing on the NASDAQ Capital Market under the symbol 'BGLC' and are expected to commence trading on July 20, 2023. The offering is expected to close on July 24, 2023.

Portfolio Pulse from Happy Mohamed

July 20, 2023 | 5:29 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.